Since its inception in 2017, Eyevance remains dedicated to advancing ocular health by developing and commercializing innovative and impactful topical ophthalmic products targeting the ocular surface and anterior segment that enable optimal vision and better quality of life, while also ensuring patient access for all patients throughout the U.S. In September 2020, Eyevance was acquired by Santen Holdings U.S. Inc., a subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on ophthalmology. For additional information, visit www.eyevance.com and follow on Twitter (@EyevancePharma) and LinkedIn (Eyevance Pharmaceuticals).